N/A Completed N=78 Randomized Single-blind Treatment

Baerveldt 350 vs Ahmed ClearPath 250 for the Treatment of Glaucoma

Glaucoma

Source: ClinicalTrials.gov NCT04542616 ↗

Enrolled (actual)

Serious AEs

2.6%

Results posted

Apr 2026

Primary outcomePrimary: Intraocular Pressure (IOP) — 22.58; 20.95; 15.0; 15.1 mmHg

Summary

To compare the safety and efficacy of Baerveldt 350 and Ahmed ClearPath 250 tube shunts in lowering IOP in glaucoma patients.

Outcome Measures

Outcome	Result	p-value
PRIMARY Intraocular Pressure (IOP)	22.58; 20.95; 15.0; 15.1; 11.7; 12.1	—

Eligibility Criteria

Inclusion Criteria

Significant uncontrolled glaucoma despite medical, laser or previous surgical therapy that requires tube shunt implantation as standard-of-care to stabilize the glaucoma and preserve vision.
Pseudophakia
Patients who are willing to participate and are able to understand and sign the study consent form.
Age ≥18 years.

Exclusion Criteria

Phakic eyes (no previous cataract surgery).
Aphakic eyes (status post previous cataract removal but without a lens implant).
Age <18 years.
Women of child-bearing age.
Patients unable to comprehend and sign the study consent form.
Women who are pregnant.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04542616). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.